Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis.

Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, Wright TL, Keeffe EB.

Clin Gastroenterol Hepatol. 2004 Sep;2(9):820-4.

PMID:
15354283
2.

Epidemiology of alcoholic liver disease.

Mandayam S, Jamal MM, Morgan TR.

Semin Liver Dis. 2004 Aug;24(3):217-32. Review.

PMID:
15349801
3.

Hepatic encephalopathy: a review.

Lizardi-Cervera J, Almeda P, Guevara L, Uribe M.

Ann Hepatol. 2003 Jul-Sep;2(3):122-30. Review.

PMID:
15115963
4.

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.

Als-Nielsen B, Gluud LL, Gluud C.

BMJ. 2004 May 1;328(7447):1046. Epub 2004 Mar 30. Review.

5.

The relation of the trail making test to organic brain damage.

REITAN RM.

J Consult Psychol. 1955 Oct;19(5):393-4. No abstract available.

PMID:
13263471
6.

Challenges of designing hepatic encephalopathy treatment trials.

Sanaka MR, Ong JP, Mullen KD.

Hepatology. 2003 Aug;38(2):527-8. No abstract available.

PMID:
12903650
7.

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group.

J Hepatol. 2003 Jan;38(1):51-8.

PMID:
12480560
8.

Management of hepatic encephalopathy.

Kircheis G, Häussinger D.

J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S260-7. Review.

PMID:
12472947
9.
10.

Effect of race on outcome of orthotopic liver transplantation: a cohort study.

Nair S, Eustace J, Thuluvath PJ.

Lancet. 2002 Jan 26;359(9303):287-93.

PMID:
11830194
11.

Hepatic Encephalopathy.

Blei AT, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology.

Am J Gastroenterol. 2001 Jul;96(7):1968-76.

PMID:
11467622
12.
13.

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.

Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T.

Hepatology. 1999 Sep;30(3):787-93.

PMID:
10462387
14.

Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma.

Huh K, Choi SY, Whang YS, Lee DS.

J Korean Med Sci. 1998 Jun;13(3):306-10.

15.

Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.

Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T, Kawasaki H, Okita K, Tanikawa K, Fujiyama S, Shimada S.

Hepatology. 1997 Dec;26(6):1410-4.

PMID:
9397979
16.

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

Miglio F, Valpiani D, Rossellini SR, Ferrieri A.

Curr Med Res Opin. 1997;13(10):593-601.

PMID:
9327194
17.

Treatment of hepatic encephalopathy.

Riordan SM, Williams R.

N Engl J Med. 1997 Aug 14;337(7):473-9. Review. No abstract available.

PMID:
9250851
18.

Lactulose, disaccharides and colonic flora. Clinical consequences.

Clausen MR, Mortensen PB.

Drugs. 1997 Jun;53(6):930-42. Review.

PMID:
9179525
19.

Supplemental Content

Support Center